Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

A compound of formula (I)

• or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein:
• n is 1 or 2;
• R1 is cycloalkyl or heterocycle, each of which is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of alkyl, alkenyl, haloalkyl, Cl, Br, F, I, —CN, —NO2, —ORb, —SRb, —S(O)RZ, —S(O)2RZ, —NaRb, —C(O)Rb, —C(O)ORb, —C(O)NRaRb, —S(O)2NRaRb, —C(═NOH)NH2, —C(═NH)NH2, Rc, —(CRdRe)m—CN, —(CRdRe)m—ORb, —(CRdRe)m—SRb, —(CRdRe)m—S(O)2RZ, —(CRdRe)m—NRaRb, —(CRdRe)m—C(O)Rb, —(CRdRe)m—C(O)ORb, —(CRdRe)m—S(O)2NRaRb, —(CRdRe)m—Rc —N(Ra)—(CRdRe)m—C(O)Rb, —N(Ra)—(CRdRe)m—C(O)ORb, —N(Ra)—(CRdRe)m—C(O)NRaRb, O—(CRdRe)m—C(O)Rb, —O—(CRdRe)m—C(O)ORb, and —O—(CRdRe)m—C(O)NRaRb;
• R2 and R3, at each occurrence, are each independently hydrogen, alkyl, Rc or —(CRdRe)m—Rc or R2 and R3 taken together with the atoms to which they are attached form a cycloalkyl;
• R4 is -E-G or —(CRdRe)m-E-G, wherein E, at each occurrence, is independently O, S. S(O), S(O)2, N(Re), or a bond and G, at each occurrence, is independently alkyl, haloalkyl, —(CRdRe)m—ORd, —(CRdRe)m—C(O)ORd, —RA, or —(CRdRe)m—RA, wherein RA, at each occurrence, is independently selected from the group consisting of aryl, heteroaryl, cycloalkyl and heterocycle, and each RA is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of alkyl, alkenyl, haloalkyl, Cl, Br, F. I, —CN5-NO2, —ORd, —S(Rd), —S(O)(alkyl), —S(O)(haloalkyl), —S(O)2(alkyl), —S(O)2(haloalkyl), —NRdRe, —C(O)(Rd), —C(O)ORd, —C(O)NRdRe, —S(O)2NRdRe, Rc, —(CRdRe)m—CN, —(CRdRe)m—NO2, —(CRdRe)m—ORd, —(CRdRe)m—S(Rd), —(CRdRe)m—S(O)(alkyl), —(CRdRe)m—S(O)(haloalkyl), —(CRdRe)m—S(O)2(alkyl), —(CRdRe)m—S(O)2(haloalkyl), —(CRdRe)m—NRdRe, —(CdRe)m—C(O)(Rd), —(CRdRe)m—C(O)ORd, —(CRdRe)m—C(O)NRdRe, —(CRdRe)m—S(O)2NRdRe, and —(CRdRe)m—Re;
• Ra, at each occurrence, is independently hydrogen or alkyl;
• Rb, at each occurrence, is independently hydrogen, alkyl, haloalkyl, Re or —(CRdRe)m—Rc;
• Rz, at each occurrence, is independently alkyl, haloalkyl, Re or —(CRdRe)m—Re;
• Re, at each occurrence, is independently aryl, heteroaryl, cycloalkyl or heterocycle;
• wherein each Re is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of alkyl, alkenyl, haloalkyl, Cl, Br, F, I, —CN, —NO2, —ORd, —S(Rd), —S(O)(alkyl), —S(O)(haloalkyl), —S(O)2(alkyl), —S(O)2(haloalkyl), —NRdRe, —C(O)(Rd), —C(O)ORd, —C(O)NRdRe, —S(O)2NRdRe, —(CRdRe)m—CN, —(CRdRe)m—NO2, —(CRdRe)m—ORd, —(CRdRe)m—S(Rd), —(CRdRe)m—S(O)(alkyl), —(CRdRe)m—S(O)(haloalkyl), —(CRdRe)m—S(O)2(alkyl), —(CRdRe)m—S(O)2(haloalkyl), —(CRdRe)m—NRdRe, —(CRdRe)m—C(O)(Rd), —(CRdRe)m—C(O)ORd, —(CRdRe)m—C(O)NRdRe, and —(CRdRe)m—S(O)2NRdRe;
• Rd and Re, at each occurrence, are independently hydrogen, alkyl or haloalkyl;
• and
• m is 0, 1, 2, 3, 4, 5 or 6.